The Covid-19 pandemic has made a dramatic difference in our private and professional lives. In the pharmaceutical industry, changes that occurred were most evident in the approach to inspections by competent authorities and audits by manufacturers of their suppliers.
In early 2020, at the beginning of the pandemic, all inspections and audits were simply suspended until the situation stabilized. Back then, no one expected that such a situation would last a long time. After a few months, both agencies and manufacturers of medicinal products realized that despite the existing restrictions, ensuring the quality of the supply chain must be continued. For this reason, the idea of remote inspections came about and they have now been implemented.